IRIX250117C2500
- 0.05
- 0.000.00%
IRIDEX Newsroom
Iridex Publishes Peer-Reviewed Study In Ophthalmology Therapy; Highlights Safety And Efficacy Of MicroPulse Transscleral Laser Therapy In Managing Both Primary And Secondary Glaucoma Over Five Years.
Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management
Iridex CEO Patrick Mercer Joins Board of Directors
Iridex Corporation Confirms Adoption of Local Coverage Determination L37531 for Micro-Invasive Glaucoma Surgery
Express News | Iridex Confirms That Local Coverage Determination L37531, Relating To Micro-Invasive Glaucoma Surgery Was Adopted As Scheduled And Wll Be Effective For Services Performed After Nov. 17
Express News | IRIDEX Corp: Encouraged That Transscleral Cyclophotocoagulation Remains Unaffected by Recent Glaucoma Lcd
Express News | IRIDEX Corp: IRIDEX's Cyclo G6 Product Family Is Unaffected by New Reimbursement Limitations
Express News | IRIDEX Comments on Changing Glaucoma Reimbursement Landscape
Iridex Comments on Changing Glaucoma Reimbursement Landscape
IRIDEX Corporation (IRIX) Q3 2024 Earnings Call Transcript Summary
Iridex Leadership Changes and Strategic Appointments
Express News | IRIDEX Shares Are Trading Higher. The Company Reported Q3 Financial Results
IRIDEX Corp (IRIX) Q3 2024 Earnings Call Highlights: Strategic Moves and Glaucoma Growth Amid ...
Iridex: Will Engage With Global Contract Manufacturing Partners to Improve Gross Margins Through Increased Outsourcing >IRIX
Iridex: Implemented a Series of Additional Operating Improvements and Cost-Cutting Measures >IRIX
Iridex Q3 EPS $(0.12) Misses $(0.09) Estimate, Sales $11.58M Miss $12.50M Estimate
IRIDEX | 10-Q: Q3 2024 Earnings Report
IRIDEX | 8-K: Iridex Reports Third Quarter 2024 Financial Results
Earnings Flash (IRIX) IRIDEX CORPORATION Posts Q3 Revenue $11.6M
Express News | IRIDEX Q3 Operating Expenses USD 6.2 Million